<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401542</url>
  </required_header>
  <id_info>
    <org_study_id>B-701-U21</org_study_id>
    <secondary_id>2017-001319-36</secondary_id>
    <nct_id>NCT02401542</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma</brief_title>
  <acronym>FIERCE 21</acronym>
  <official_title>A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects Who Have Relapsed After, or Are Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioClin Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioClin Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, randomized, double-blind, placebo-controlled, multicenter,
      parallel-group study of B-701 plus docetaxel versus placebo plus docetaxel in the treatment
      of locally advanced or metastatic urothelial cell carcinoma in subjects who have relapsed
      after, or are refractory to standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, randomized, double-blind, placebo-controlled, multicenter,
      parallel-group, efficacy and safety study of B-701 plus docetaxel versus placebo plus
      docetaxel in the treatment of subjects with Stage IV, locally advanced or metastatic UCC who
      have relapsed after, or are refractory to at least one prior line of chemotherapy. This study
      is divided into 2 phases: Lead-In Phase and Randomized Phase; and the Lead-In Phase is
      divided into 3 cohorts. In Cohorts 1 and 2, all subjects will receive both B-701 plus
      docetaxel (unblinded). In Cohort 3, all subjects will receive B-701 only (unblinded).
      Subjects enrolling in Cohorts 2 and 3, as well as the Randomized Phase of the study, must
      have tumors with FGFR3 mutations or gene fusions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by progression-free survival (PFS)</measure>
    <time_frame>up to 3-4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by objective response rates (ORR)</measure>
    <time_frame>up to 3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by disease control rate (DCR)</measure>
    <time_frame>up to 3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by duration of objective response (DOR)</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by overall survival (OS)</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of B-701 plus docetaxel compared with placebo plus docetaxel as measured by quality of life (QOL)</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed through summaries of AEs</measure>
    <time_frame>3-4 years</time_frame>
    <description>Evaluate the safety and tolerability of B-701 plus docetaxel compared with placebo plus docetaxel in the treatment of subjects with UCC as measured by AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed through summaries of physical examination findings</measure>
    <time_frame>3-4 years</time_frame>
    <description>Evaluate the safety and tolerability of B-701 plus docetaxel compared with placebo plus docetaxel in the treatment of subjects with UCC as measured by physical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed through summaries of laboratory laboratory results</measure>
    <time_frame>3-4 years</time_frame>
    <description>Evaluate the safety and tolerability of B-701 plus docetaxel compared with placebo plus docetaxel in the treatment of subjects with UCC as measured by laboratory results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed through summaries of ECG results.</measure>
    <time_frame>3-4 years</time_frame>
    <description>Evaluate the safety and tolerability of B-701 plus docetaxel compared with placebo plus docetaxel in the treatment of subjects with UCC as measured by electrocardiogram (ECG) results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate FGFR3 Expression</measure>
    <time_frame>3-4 years</time_frame>
    <description>To study the association between the level of FGFR3 expression in primary tumors or metastases with efficacy and/or adverse event (AE) outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of FGFR3 mutations or fusions in primary tumors or metastases</measure>
    <time_frame>3-4 years</time_frame>
    <description>To study the association between the presence of FGFR3 mutations or fusions in primary tumors or metastases with efficacy and/or adverse event (AE) outcomes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Locally Advanced or Metastatic Urothelial Cell Carcinoma</condition>
  <condition>Urinary Bladder Disease</condition>
  <condition>Urological Diseases</condition>
  <arm_group>
    <arm_group_label>B-701 plus docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion B-701, 25 mg/kg plus docetaxel, 75 mg/m2 on day one of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus docetaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion placebo plus docetaxel, 75 mg/m2 on day one of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion B-701, 25 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-701</intervention_name>
    <arm_group_label>B-701 plus docetaxel</arm_group_label>
    <arm_group_label>B-701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>B-701 plus docetaxel</arm_group_label>
    <arm_group_label>Placebo plus docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo plus docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Available tissue that was obtained at or after the time the usbject was found to have
             muscle invasive disease and is of suitable quality and quantity and to assess the
             FGFR3 status by genetic testing. For subjects participating in the Randomized Phase
             only, if suitable archival tissue is unavailable, then a core biopsy of tumor tissue
             (metastatic or primary) must be obtained prior to randomization even if a blood sample
             sample was used to determine FGFR3 genetic status

          -  Stage IV, locally advanced or metastatic urothelial bladder cancer or transitional
             cell carcinoma arising in another location of the urinary tract, including urethra,
             ureter, and renal pelvis

          -  Relapsed after or are refractory to at least one prior line of chemotherapy which have
             not included a taxane (with the exception of Cohort 3 of the Lead-In Phase which will
             allow the enrollment of subjects with prior treatment with a taxane)

          -  At least one prior chemotherapeutic regimen for advanced metastatic/recurrent disease,
             of which at least one regimen included a platinum agent (unless contraindicated)

          -  Measurable disease according to RECIST v1.1 criteria

          -  For Cohort 2, Cohort 3, and the Randomized Phase, tumor must be shown to have an FGFR3
             mutation or gene fusion.

        Main Exclusion Criteria:

          -  Prior anti-cancer therapy within 4 weeks prior to Cycle 1, Day 1

          -  Prior treatment with an inhibitor that is targeted primarily to FGFRs

          -  Clinically significant comorbid medical conditions or lab abnormalities

          -  History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a
             tumor within the past 12 months

          -  History of clinically significant coagulation or platelet disorder in the past 12
             months

          -  Currently receiving anticoagulation treatment

          -  Incomplete healing from wounds from prior surgery

          -  Weight &gt; 110kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Izzy Cornelio</last_name>
    <phone>(323) 401-3093</phone>
    <email>icornelio@bioclintherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Werner Gladdines</last_name>
    <email>wgladdines@bioclintherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <zip>60023</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>136075</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>435</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002 R.O.C.</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>İstanbul</city>
        <zip>34732</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>İzmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial Cell Carcinoma</keyword>
  <keyword>UCC</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>B-701</keyword>
  <keyword>FGFR3</keyword>
  <keyword>invasive bladder cancer</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>Transitional Cell Carcinoma</keyword>
  <keyword>TCC</keyword>
  <keyword>Phase 2</keyword>
  <keyword>second line therapy</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>docetaxel</keyword>
  <keyword>combination therapy</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

